Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy

Andrea Chiricozzi, Angelo Massimiliano D’Erme, Marco Romanelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

15 Citazioni (Scopus)

Abstract

Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor α subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD.
Lingua originaleEnglish
pagine (da-a)1473-1480
Numero di pagine8
RivistaDrug Design, Development and Therapy
Volume11
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • 3003
  • Adult
  • Antibodies, Monoclonal
  • Atopic dermatitis
  • Biologics
  • Child
  • Dermatitis, Atopic
  • Drug Discovery3003 Pharmaceutical Science
  • Dupilumab
  • Eczema
  • Humans
  • IL-13
  • IL-4
  • Interleukin-13
  • Interleukin-4
  • Interleukin-4 Receptor alpha Subunit
  • Pharmacology
  • Severity of Illness Index
  • Th2 Cells

Fingerprint

Entra nei temi di ricerca di 'Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy'. Insieme formano una fingerprint unica.

Cita questo